# US 2004/0082064 A1 · Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0082064 A1
- Document ID: US20040082064A1
- Status: Published application
- Kind: A1
- Application number: 10/379,725
- Filed: 2003-03-06
- Published: 2004-04-29
- Earliest claimed: 2001-09-07
- Assignees: Yeda Research and Development Co. Ltd.
- Inventors: Yair Reisner; Benjamin Dekel
- Web page: https://patentgrep.com/patent/US20040082064A1

## CPC

- A61K 35/22: Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
- A61P 13/12: of the kidneys
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method of treating a disorder associated with pathological organ or tissue physiology or morphology is disclosed. The method is effected by transplanting into a subject in need thereof a therapeutically effective mammalian organ or tissue graft selected not substantially expressing or presenting at least one molecule capable of stimulating or enhancing an immune response in the subject.

## Claims

### Claim 1

A method of treating a disorder associated with pathological organ or tissue physiology or morphology, the method comprising transplanting into a subject in need thereof a therapeutically effective mammalian organ or tissue graft, said organ or tissue graft selected not substantially expressing or presenting at least one molecule capable of stimulating or enhancing an immune response in said subject, thereby treating the disorder in said subject.

### Claim 2 (depends on 1)

The method of claim 1, further comprising treating said subject with an immunosuppressive regimen prior to, concomitantly with or following said transplanting said organ or tissue graft into said subject, thereby promoting engraftment of said organ or tissue graft in said subject.

### Claim 3 (depends on 2)

The method of claim 2, wherein said treating said subject with an immunosuppressive regimen is effected by administering an immunosuppressant drug to said subject.

### Claim 4 (depends on 3)

The method of claim 3, wherein said immunosuppressant drug is capable of blocking binding of a lymphocyte coreceptor with a ligand of said lymphocyte coreceptor.

### Claim 5 (depends on 4)

The method of claim 4, wherein said immunosuppressant drug is CTLA4-Ig.

### Claim 6 (depends on 3)

The method of claim 3, wherein, said administering an immunosuppressant drug to said subject is effected during a single time period selected from a range of 1 to 20 days.

### Claim 7 (depends on 1)

The method of claim 1, wherein said at least one molecule capable of stimulating or enhancing an immune response in said subject is a lymphocyte coreceptor or lymphocyte coreceptor ligand.

### Claim 8 (depends on 7)

The method of claim 7, wherein said lymphocyte coreceptor or lymphocyte coreceptor ligand is selected from the group consisting of B7-1, CD40, and CD40L.

### Claim 9 (depends on 1)

The method of claim 1, wherein said selecting said organ or tissue graft is effected via RT-PCR analysis of said organ or tissue graft.

### Claim 10 (depends on 1)

The method of claim 1, wherein said organ or tissue graft is a renal organ or tissue graft, and whereas said transplanting said organ or tissue graft into said subject is effected by transplanting said organ or tissue graft into an anatomical location of said subject selected from the group consisting of the renal capsule, the kidney, the testicular fat, the sub-cutis, the omentum and the intra-abdominal space.

### Claim 11 (depends on 1)

The method of claim 1, wherein said organ or tissue graft is a pancreatic organ or tissue graft, and whereas said transplanting said organ or tissue graft into said subject is effected by transplanting said organ or tissue graft into an anatomical location of said subject selected from the group consisting of the portal vein, the liver, the pancreas, the renal capsule, the testicular fat, the sub-cutis, the omentum and the intra-abdominal space.

### Claim 12 (depends on 1)

The method of claim 1, wherein the disorder is a kidney disorder, and whereas said organ or tissue graft is a renal organ or tissue graft.

### Claim 13 (depends on 1)

The method of claim 1, wherein the disorder is a pancreatic disorder, and whereas said organ or tissue graft is a pancreatic organ or tissue graft.

### Claim 14 (depends on 13)

The method of claim 13, wherein said pancreatic disorder is diabetes, and whereas said pancreatic organ or tissue graft is a pancreatic islet organ or tissue graft.

### Claim 15 (depends on 14)

The method of claim 14, wherein said subject is a mammal.

### Claim 16 (depends on 15)

The method of claim 15, wherein said mammal is a human.

### Claim 17 (depends on 1)

The method of claim 1, wherein said mammalian organ or tissue graft is a human organ or tissue graft, or a porcine organ or tissue graft.

### Claim 18

A method of treating a disorder associated with pathological organ or tissue physiology or morphology, the method comprising transplanting into a subject in need thereof a therapeutically effective human organ or tissue graft, said human organ or tissue graft selected at a stage of differentiation corresponding to 5 to 16 weeks of gestation, thereby treating the disorder in the subject.

### Claim 19 (depends on 18)

The method of claim 18, wherein said stage of differentiation corresponds to 6 to 15 weeks of gestation.

### Claim 20 (depends on 19)

The method of claim 19, wherein said stage of differentiation corresponds to 7 to 14 weeks of gestation.

### Claim 21 (depends on 20)

The method of claim 20, wherein said stage of differentiation corresponds to 7 to 8 weeks of gestation.

### Claim 22

A method of treating a disorder associated with pathological organ or tissue physiology or morphology, the method comprising transplanting into a subject in need thereof a therapeutically effective porcine organ or tissue graft, said porcine organ or tissue graft selected at a stage of differentiation corresponding to 20 to 63 days of gestation, thereby treating the disorder in the subject.

### Claim 23 (depends on 22)

The method of claim 22, wherein said stage of differentiation corresponds to 20 to 56 days of gestation.

### Claim 24 (depends on 23)

The method of claim 23, wherein said stage of differentiation corresponds to 20 to 42 days of gestation.

### Claim 25 (depends on 24)

The method of claim 24, wherein said stage of differentiation corresponds to 20 to 35 days of gestation.

### Claim 26 (depends on 25)

The method of claim 25, wherein said stage of differentiation corresponds to 20 to 28 days of gestation.

### Claim 27 (depends on 26)

The method of claim 26, wherein said stage of differentiation corresponds to 24 to 28 days of gestation.

### Claim 28 (depends on 27)

The method of claim 27, wherein said stage of differentiation corresponds to 27 to 28 days of gestation.

### Claim 29

A method of evaluating the suitability of a graft for transplantation into a subject, the method comprising testing the graft for expression or presentation of at least one molecule capable of stimulating or enhancing an immune response in the subject, thereby evaluating the suitability of the graft for transplantation into the subject.

### Claim 30 (depends on 29)

The method of claim 29, wherein said at least one molecule capable of stimulating or enhancing an immune response in the subject is a lymphocyte coreceptor or lymphocyte coreceptor ligand.

### Claim 31 (depends on 30)

The method of claim 30, wherein said lymphocyte coreceptor or lymphocyte coreceptor ligand is selected from the group consisting of B7-1, CD40 and CD40L.

### Claim 32 (depends on 29)

The method of claim 29, wherein said testing is effected via RT-PCR analysis of the graft.

### Claim 33 (depends on 29)

The method of claim 29, wherein the graft is selected from the group consisting of an organ explant, a tissue explant, a cell explant, an organ culture, a tissue culture, and a cell culture.

### Claim 34 (depends on 29)

The method of claim 29, wherein the subject is a mammal.

### Claim 35 (depends on 34)

The method of claim 34, wherein said mammal is a human.

### Claim 36 (depends on 29)

The method of claim 29, wherein the graft is a mammalian graft.

### Claim 37 (depends on 36)

The method of claim 36, wherein said mammalian graft is a human graft or a porcine graft.

### Claim 38

A method of evaluating the stage of differentiation of a mammalian organ or tissue most suitable for transplantation thereof into a mammalian subject, the method comprising evaluating a test transplant taken from the organ or tissue at a specific stage of differentiation for the presence of at least one molecule capable of stimulating or enhancing an immune response in the subject prior to and/or following a test transplantation of said test transplant into a mammalian test recipient, wherein an effective absence of said at least one molecule in said test transplant prior to and/or following said test transplantation indicates that said specific stage of differentiation is suitable for transplantation of the organ or tissue into the subject.

### Claim 39 (depends on 38)

The method of claim 38, wherein said evaluating said test transplant for said presence of said at least one molecule is effected following a posttransplantation period of said test transplantation selected from the range of 1 second to 45 days.

### Claim 40 (depends on 38)

The method of claim 38, wherein said test recipient is a rodent and/or the subject.

### Claim 41 (depends on 40)

The method of claim 40, wherein said rodent is a mouse.

### Claim 42 (depends on 38)

The method of claim 38, wherein said test recipient bears functional human T lymphocytes.

### Claim 43 (depends on 42)

The method of claim 42, wherein said human T lymphocytes and said organ or tissue are non syngeneic.

### Claim 44 (depends on 38)

The method of claim 38, wherein said at least one molecule capable of stimulating or enhancing an immune response in the subject is a lymphocyte coreceptor or lymphocyte coreceptor ligand.

### Claim 45 (depends on 44)

The method of claim 44, wherein said lymphocyte coreceptor or lymphocyte coreceptor ligand is selected from the group consisting of B7-1, CD40 and CD40L.

### Claim 46 (depends on 38)

The method of claim 38, wherein said testing is effected via RT-PCR analysis of the test transplant.

### Claim 47 (depends on 38)

The method of claim 38, wherein the organ or tissue is selected from the group consisting of an organ explant, a tissue explant, a cell explant, an organ culture, a tissue culture, and a cell culture.

### Claim 48 (depends on 38)

The method of claim 38, wherein the organ or tissue is a human organ or tissue or a porcine organ or tissue.

### Claim 49 (depends on 48)

The method of claim 48, wherein the organ or tissue is a human organ or tissue and whereas said specific stage of differentiation is selected corresponding to 5 to 16 weeks of gestation.

### Claim 50 (depends on 48)

The method of claim 48, wherein the organ or tissue is a porcine organ or tissue and whereas said specific stage of differentiation is selected corresponding to 20 to 63 days of gestation.
